Navigation Links
Trovagene, Inc. Reports Third Quarter 2013 Financial Results

SAN DIEGO, Nov. 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, today reported financial results for the three months and the nine months ended September 30, 2013.


"We have made significant corporate and scientific achievements in recent months. We have signed multiple collaboration agreements and launched our first oncogene mutation detection test. In addition, the first series of clinical results were presented at a major medical conference. These data demonstrated the detection and monitoring of cancer mutations in urine with high rates of sensitivity," stated Antonius Schuh, Ph.D., chief executive officer of Trovagene. "Trovagene is well positioned to leverage its investment in its intellectual property, scientific research, and collaborations to build a better clinical pathway for cancer monitoring."

Third Quarter 2013 Financial Results
For the three months ended September 30, 2013, Trovagene reported a net loss available to common stockholders of $4.4 million, or $0.25 per share, as compared to a net loss available to common stockholders of $0.66 million, or $0.05 per share, for the three months ended September 30, 2012. The increase in net loss available to common stockholders was primarily due to an increase in total operating expenses of $1.87 million, or $0.10 per share, as well as an increase in the change in fair value of derivative instruments related to warrants of $1.71 million, $0.09 per share, during the third quarter of 2013, as compared to the prior year comparable period.

First Nine Months Financial Results
For the nine months ended September 30, 2013, Trovagene reported a net loss available to common stockholders of $10.8 million, or $0.66 per share, as compared to a net loss available to common stockholders of $5.3 million, or $0.42 per share, for the nine months ended September 30, 2012. The increase in net loss available to common stockholders is primarily attributable to an increase in total operating expenses of $4.4 million, or $0.27 per share, and an increase in the change in fair value of derivative instruments related to warrants of $1.1 million, $0.07 per share, as compared to the prior year comparable period.

Cash and Cash Equivalents
Trovagene had cash and cash equivalents of approximately $28 million at September 30, 2013, as compared to $11 million at December 31, 2012. The Company completed a $15 million registered direct offering on July 31, 2013.

Review of Recent 2013 Announcements Demonstrate Progress in Development Programs

  • Presented first prospective cancer monitoring data demonstrating that Trovagene's diagnostics can detect rare oncogene mutation signals in urine that closely correlate to tissue biopsy and response to therapy.
  • Launched cell-free BRAF oncogene diagnostic, the first urine-based cancer mutation monitoring test.
  • Entered into collaboration with an undisclosed pharmaceutical company to study oncogene detection and monitoring in lung cancer. Initiated clinical collaboration with USC Norris Cancer Center to study genomic characterizations of metastatic colorectal cancers using Trovagene's proprietary cell-free DNA assays.
  • Completed $15 million registered direct offering of common stock.
  • Webcast of Earnings Conference Call
    Trovagene's management team will host an earnings conference call on Thursday, November 14, 2013, at 5:00 p.m. Eastern Standard Time (2:00 p.m. Pacific Standard Time). Interested parties may listen to a live audio broadcast of the conference call on the Company's website in the Investor Room. A replay of the call can be accessed approximately one hour after the completion of the call and will be archived on the website for at least one year.

    About Trovagene, Inc.
    Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

     (Financial Information to Follow)ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

    Chief Financial OfficerAmy Caterina

    Investor RelationsTrovagene, Inc.Trovagene, 



    Trovagene, Inc. and Subsidiaries
    (A Development Stage Company)
    Selected Financial Information
    Consolidated Condensed Statements of Operations and Comprehensive Loss 

    (in thousands, except for per share amounts) Three Months Ended
    September 30,Nine Months Ended
    September 30,2013201220132012(Unaudited)(Unaudited)Revenues$




    287Operating expenses:Research and development 9165112,6621,326General and administrative 2,2067395,3922,376Total operating expenses3,1221,2508,0533,702Operating loss(3,078)(1,039)(7,842)(3,415)Interest expense(6)-(7)-Change in fair value of derivative instruments - warrants(1,317)389(2,933) 

    (1,824)Net loss and comprehensive loss$




    (5,239)Preferred stock dividend(5)(10)(21)(29)Net loss and comprehensive loss available to common stockholders$




    (5,268)Basic and diluted net loss per share$




    (0.42)Weighted average shares outstanding- basic and dilute17,87114,17816,33012,507 




    Trovagene, Inc. and Subsidiaries(A Development Stage Company)Consolidated Condensed Balance Sheet Information (in thousands) September 30,
    2013December 31,
    2012(Unaudited) Cash and cash equivalents$


    10,820Other assets611590Property and equipment, net740255Total assets$


    11,665Current portion of long-term debt$


    -Accounts payable, accrued expenses and other liabilities1,213730Long-term debt, less current portion370-Derivative financial instruments6,2818,766Stockholders' equity 21,1382,169Total liabilities and stockholders' equity$



    SOURCE Trovagene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
    2. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
    3. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    4. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    5. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    7. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    8. Pharmasset Reports Fiscal Year End 2011 Financial Results
    9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    10. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    11. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    Post Your Comments:
    (Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
    (Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
    (Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
    (Date:11/24/2015)... ... 2015 , ... International Society for Pharmaceutical Engineering (ISPE) closed ... events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in Philadelphia, ... number of attendees in more than a decade. , “The 2015 Annual ...
    Breaking Biology Technology:
    (Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
    (Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
    (Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
    Breaking Biology News(10 mins):